

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - TF Members and Additional Contributors

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Anastasakis Aris	None declared (2011-2012-2013-2014)
Borger Michael A	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : heart valve therapy (2011-2012-2013-2014)</li> <li>- Medtronic : heart valve therapy (2012-2013)</li> <li>- St. Jude Medical : heart valve therapy (2012-2013-2014)</li> <li>- Sorin Group : heart valve therapy (2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- St Jude Medical : heart valve therapy (2011)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Medtronic : heart valve therapy (2011)</li> </ul>
Borggreffe Martin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- St Jude Medical : Catheters (2011-2012)</li> <li>- Bard : Catheters (2011-2012)</li> <li>- Boehringer-Ingelheim : Drugs (2011-2012-2013-2014)</li> <li>- Sanofi Aventis : Drugs (2011-2012-2013-2014)</li> <li>- Bayer Healthcare : Drugs (2011-2012-2013-2014)</li> <li>- Medtronic : Medical devices (2011-2012-2013-2014)</li> <li>- Impulse Dynamics : Medical devices (2011-2012-2013-2014)</li> <li>- Boston Scientific : Stents, Catheter (2011-2012-2013-2014)</li> <li>- VEST : Medical devices (2012)</li> <li>- St Jude Medical : Catheters, ICD (2013-2014)</li> <li>- Novartis : Drugs (2013-2014)</li> <li>- Zoll Medical : Medical devices (2013-2014)</li> <li>- Daiichi Sankyo : drugs (2014)</li> </ul>

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - TF Members and Additional Contributors

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Borggreve Martin	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Drugs (2011-2012-2013-2014)</li> <li>- Pfizer : Drugs (2011-2012-2013-2014)</li> <li>- Sanofi Aventis : Drugs (2011-2012-2013-2014)</li> <li>- Medtronic : Medical devices (2011-2012-2013-2014)</li> <li>- St Jude Medical : Medical devices (2011-2012-2013-2014)</li> <li>- Impulse Dynamics : Medical devices (2011-2012-2013-2014)</li> <li>- VEST : Medical devices (2012)</li> <li>- Zoll Medical : Medical devices (2013-2014)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Thieme Verlag : Author ship (2011-2012)</li> <li>- Thieme Verlag : Authorship (2013-2014)</li> </ul>
Cecchi Franco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Genzyme : Fabrazyme (2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Genzyme : Fabrazyme (2011-2012-2013-2014)</li> </ul>
Charron Philippe	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary hypertension (2011)</li> <li>- Genzyme : Lysosomal diseases (2011-2012-2013-2014)</li> <li>- Servier : Heart failure and CAD (2012-2013)</li> <li>- Shire HGT : Lysosomal diseases (2012-2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Shire HGT : Lysosomal diseases (2014)</li> </ul>
Elliott Perry Mark	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Shire HGT : Enzyme replacement therapy Fabry disease (2011-2012-2013-2014)</li> <li>- Genzyme : Enzyme replacement therapy Fabry disease (2011-2012-2013-2014)</li> </ul>

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - TF Members and Additional Contributors

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Elliott Perry Mark	<ul style="list-style-type: none"> <li>- Pfizer : Treatment for TTR amyloidosis (2011-2012-2013-2014)</li> <li>- Gilead : Ranolazine (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Genzyme : Cardiac magnetic resonance imaging in HCM (2011-2012-2013-2014)</li> <li>- Shire HGT : Clinical characterisation of Anderson-Fabry Disease (2011-2012-2013-2014)</li> <li>- National Institute for Health and Clinical Excellence : Genetics of hypertrophic cardiomyopathy (2011-2012-2013-2014)</li> <li>- British Heart Foundation : Hypertrophic cardiomyopathy (2011-2012-2013-2014)</li> </ul>
Hagege Albert Alain	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : hypertension (2011-2012-2013)</li> <li>- Daiichi Sankyo : hypertension (2011-2012-2013)</li> <li>- Astra Zeneca : candesartan. crestor (2011-2012-2013-2014)</li> <li>- Genzyme : fabrazyme. hypercholesterolemia (2011-2012-2013-2014)</li> <li>- Sorin Group : heart failure (2011-2012-2013-2014)</li> <li>- Novartis : hypertension. heart failure (2011-2012-2013-2014)</li> <li>- Menarini : hypertension. heart failure (2011-2012-2013-2014)</li> <li>- Eli Lilly : prasugrel (2011-2012-2013-2014)</li> <li>- Bayer Healthcare : anticoagulant (2012-2013-2014)</li> <li>- Bristol Myers Squibb : anticoagulant (2012-2013-2014)</li> <li>- MSD : hypercholesterolemia (2012-2013-2014)</li> <li>- Gilead : Hypertrophic cardiomyopathy (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Genzyme : Fabrazyme (Fabry disease) (2011-2012-2013-2014)</li> <li>- Sorin Group : Heart failure (2014)</li> </ul>

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - TF Members and Additional Contributors

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hagege Albert Alain	E - Research funding (personal). - Pierre-Fabre : omega-3 (2012-2013)
Lafont Antoine	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : STENT (2011-2012-2013-2014) - Art : stent (2012-2013-2014)  D - Research funding (departmental or institutional). - Terumo Inc : STENT (2011-2012-2013-2014)
Limongelli Giuseppe	None declared (2011-2012)  A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biomarin : Lysosomal Storage Diseases (2013) - Genzyme : Lysosomal Storage Disease (2014) - Biomarin : Lysosomal Storage Disease (2014)
Mahrholdt Heiko	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Institut für Herzinfarktforschung Ludwigshafen, Germany : Consultant (2011-2012-2013-2014)  D - Research funding (departmental or institutional). - Robert Bosch Foundation : Research Grants (2011-2012-2013-2014)
McKenna William J	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Various : cardiomyopathy (2011-2012-2013-2014)  D - Research funding (departmental or institutional). - National Institute for Health Research : Cardiomyopathy (2011-2012-2013-2014) - British Heart Foundation : Cardiomyopathy (2011-2012-2013-2014)
Mogensen Jens	None declared (2011-2012-2013-2014)
Nihoyannopoulos Petros	None declared (2012)  A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bracco Pharmaceutical : Sonovue (2011) - GSK : Consultant for Imaging studies (2013-2014)
Nistri Stefano	None declared (2011-2012-2013-2014)

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - TF Members and Additional Contributors

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
O'Mahony Constantinos	None declared (2012-2013-2014)
Pieper Els Petronella G	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Sorin Group : funding for research on prosthetic heart valves in congenital heart disease (prostava study); total amount 50.000 euro; Main funding of this project is by Netherlands Heart Foundation. Funders have had no saying in the design of the study and will not be involved in the scientific output arising from this study (2011-2012-2013-2014)</li> </ul>
Pieske Burkert Mathias	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : Coronary artery disease (2011)</li> <li>- Boehringer-Ingelheim : Anticoagulation (2011-2012-2013)</li> <li>- Novartis : Heart Failure (2011-2012-2013)</li> <li>- Servier : Heart Failure (2012-2013)</li> <li>- Bayer Healthcare : Heart Failure, Pulmonary Hypertension (2012-2013)</li> <li>- Impulse Dynamics : Pacemakers (2012-2013)</li> <li>- Stealth Peptides : Acute coronary Syndrome, Heart Failure (2013)</li> <li>- Daiichio-Sankyo : Anticoagulation (2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : Device therapy (2011-2012-2013)</li> <li>- Bayer Healthcare : Heart Failure (2011-2012-2013)</li> <li>- Abbott Vascular : MitraClip (2013)</li> </ul> <p>Declaration not submitted (2014)</p>
Rapezzi Claudio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Roche Pharma : Dalcetrapib (2011-2012)</li> <li>- Servier : Ivabradine (2011-2012)</li> <li>- Pfizer : TTR related Amyloidosis (2011-2012)</li> <li>- Pfizer : tafamidis, rare diseases (2013)</li> <li>- Pfizer : rare disease, tafamidis (2014)</li> </ul>

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - TF Members and Additional Contributors

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Rapezzi Claudio	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabradine, HF and CAD (2013)</p> <p>D - Research funding (departmental or institutional). - Pfizer : Tafamidis (ATTR Amyloidosis) (2011-2012) - Pfizer : Tafamidis (2013)</p> <p>E - Research funding (personal). - Pfizer : Rare disease, tafamidis (2014)</p>
Rutten Frans Hendrik	<p>None declared (2011)</p> <p>D - Research funding (departmental or institutional). - Boehringer-Ingelheim : anticoagulation (2012) - Boehringer-Ingelheim : anticoagulants (2013) - Boehringer-Ingelheim : Atrial fibrillation (2014)</p>
Tillmanns Christoph	None declared (2011-2012-2013-2014)
Watkins Hugh	<p>None declared (2011)</p> <p>C - Receipt of royalties for intellectual property. - Harvard Medical School : Royalties from patents held by Harvard Medical School for methods for genetic testing for hypertrophic cardiomyopathy (2012-2013-2014)</p>

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Achenbach Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : CT (2012-2013)</li> <li>- Servier : Imaging (2012-2013)</li> <li>- Guerbet : Imaging (2012-2013)</li> <li>- Bayer : Anticoagulation (2013)</li> <li>- Behring : Anticoagulation (2013)</li> <li>- Astra Zeneca : Antiplatelet Therapy (2013)</li> <li>- Abbott : Coronary Intervention (2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Coronary Intervention (2013-2014)</li> <li>- Siemens Healthcare : Imaging (2013-2014)</li> </ul>
Alfonso Manterola Fernando	None declared (2012-2013-2014)
Aliyev Farid	None declared (2012-2013-2014)
Antoniades Loizos	None declared (2012-2013-2014)
Apetrei Eduard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : Atorvastatin, Amlodipin (2012-2013-2014)</li> <li>- Amgen : Darbepoetin alfa (2011,2012,2013) (2012-2013-2014)</li> <li>- Daiichi Sankyo : Edoxaban (2012-2013-2014)</li> <li>- General Electric : financial support to participate to Echo congres 2013 (2012-2013-2014)</li> <li>- Servier : Ivabradine, indapamide (2012-2013-2014)</li> <li>- Romanian Society of hypertension : lecture (2012-2013-2014)</li> <li>- Berlin Chemie AG : Nebivolol, Zofenopril .Financial support to participate to ESC congress 2013 (2012-2013-2014)</li> <li>- Astra Zeneca : Rosuvastatin (2012-2013-2014)</li> </ul>

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Apetrei Eduard	<ul style="list-style-type: none"> <li>- Sanofi Aventis : Sympposium organization (2012-2013-2014)</li> <li>- Abbott : Trandalopril (2012-2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Darabepoetin (2012-2013-2014)</li> <li>- Daiichi Sankyo : Edoxaban (2012-2013-2014)</li> </ul>
Basso Cristina	None declared (2012-2013-2014)
Bokheria Leo A	None declared (2012-2013-2014)
Brito Dulce Alves	<p>None declared (2012)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Genzyme : Enzyme replacement therapy for Fabry's Disease (2013)</li> <li>- Novartis : Heart Failure (2013-2014)</li> <li>- Orion : Heart Failure (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Heart Failure (2014)</li> <li>- Novartis : Heart Failure (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Science and Technology Foundation : Biomarkers and Cardiomyopathies (2014)</li> </ul>
Bundgaard Henning	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Cardiovascular (2012-2013)</li> <li>- MSD, AMgen : Dyslipidemia (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- AP Møller-Mærsk Foundation : Not in pharmaceutical industry (2012-2013)</li> </ul>
Carasso Shemy	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Corassist Cardiovascular Ltd : Diastolic assist device (2012-2013-2014)</li> </ul>
Cardim Nuno	None declared (2012-2013-2014)
Efthimiadis George	None declared (2012-2013-2014)



## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Eldirsi Ghada	None declared (2012-2013-2014)
Eriksson Maria J	None declared (2012-2013-2014)
Felice Tiziana	None declared (2012-2013-2014)
Frick Matthias	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : Abciximab (2012-2013-2014)</li> <li>- Novartis : Aliskiren (2012-2013-2014)</li> <li>- Biotronik : Orsiro Stent (2012-2013-2014)</li> <li>- Boehringer-Ingelheim : Pradaxa (2012-2013-2014)</li> <li>- Daiichi Sankyo : Prasugrel (2012-2013-2014)</li> <li>- Servier : Procoralan (2012-2013-2014)</li> <li>- Medtronic : Renal Sympathectomy (2012-2013-2014)</li> <li>- Astra Zeneca : Ticagrelor (2012-2013-2014)</li> <li>- Abbott Vascular : Xience and Absorb (2012-2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : Abciximab (2012-2013-2014)</li> <li>- Novartis : Aliskiren (2012-2013-2014)</li> <li>- Medicines Company : Bivalirudin (2012-2013-2014)</li> <li>- Abbott Vascular : Mitraclip, Absorb and Xience (2012-2013-2014)</li> <li>- Biotronik : Orsiro (2012-2013-2014)</li> <li>- Boehringer-Ingelheim : Pradaxa (2012-2013-2014)</li> <li>- Daiichi Sankyo : Prasugrel (2012-2013-2014)</li> <li>- Servier : Procoralan (2012-2013-2014)</li> <li>- Medtronic : Renal Ablation and Resolute Integrity Stent (2012-2013-2014)</li> </ul>

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Frick Matthias	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : statin (2012-2013-2014)</li> <li>- Astra Zeneca : Ticagrelor (2012-2013-2014)</li> <li>- Bayer : Xarelto (2012-2013-2014)</li> </ul>
Garcia-Pavia Pablo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Dabigatran (2012-2013)</li> <li>- Sanofi Aventis : Fabrazyme (2012-2013)</li> <li>- Genzyme : Fabrazyme (2012-2013)</li> <li>- Ferrer in Code : Genetic testing (2012-2013)</li> <li>- Laboratorios Rovi : Ivabradine (2012-2013)</li> <li>- Bayer Healthcare : Rivaroxaban (2012-2013)</li> <li>- Bristol Myers Squibb : Apixaban (2012-2013-2014)</li> <li>- Pfizer : Cardiovascular Drugs (2012-2013-2014)</li> <li>- Shire HGT : Replagal (2012-2013-2014)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Pfizer : Cardiovascular drugs (2012-2013-2014)</li> </ul>
Gimeno Blanes Juan Ramon	None declared (2012-2013-2014)
Gunnarsson Gunnar Thor	None declared (2012-2013-2014)
Hasdai David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Pradaxa (2012-2013-2014)</li> <li>- Bayer : Rivaroxiban (2012-2013-2014)</li> <li>- Astra Zeneca : Ticagrelor (2012-2013-2014)</li> </ul>
Hatala Robert	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : drugs (2012)</li> <li>- Bayer : drugs (2012)</li> </ul>

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hatala Robert	<ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : drugs (2012)</li> <li>- Pfizer : drugs (2012)</li> <li>- Servier : drugs (2012)</li> <li>- Bayer : antithrombotic therapy (2013)</li> <li>- Abbott : cardiovascular drugs (2013)</li> <li>- Sanofi Aventis : cardiovascular drugs (2013)</li> <li>- Boston Scientific : CRM (2013)</li> <li>- St Jude Medical : CRM (2013)</li> <li>- Boehringer-Ingelheim : antithrombotic therapy (2013-2014)</li> <li>- Pfizer : cardiovascular drugs (2013-2014)</li> <li>- Servier : cardiovascular drugs (2013-2014)</li> <li>- Medtronic : CRM (2013-2014)</li> <li>- Biotronik : CRM (2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- St Jude Medical : CRM (2012)</li> <li>- Medtronic : CRM (2012-2013-2014)</li> <li>- Biotronik : CRM (2012-2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : CRM (2012-2013-2014)</li> <li>- Biotronik : CRM (2013)</li> </ul>
Haugaa Kristina Hermann	<p>None declared (2012-2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Cardiology (2014)</li> </ul>
Helio Tiina	<p>None declared (2014)</p>

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Helio Tiina	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Genzyme : Enzyme replacement therapy (2012-2013)
Heymans Stephane	None declared (2012)  E - Research funding (personal). - Boehringer-Ingelheim : Dabigatran and Linagliptin (2013-2014)
Holm Per Johan	None declared (2013)  A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Actelion : Pulmonary hypertension (2012) - Actelion : PAH (2014)
Kamzola Ginta	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GlaxoSmithKline : Acute coronary syndrome, Speaker fee (2012) - Novartis Pharma Serv. AG : Echocardiography in terms of clinical trial (2012-2013) - Pfizer : Heart failure. Speaker fee (2012-2013) - Merck Serono : Heart failure. Speaker fee (2012-2013) - Servier : Heart failure, Speaker fee (2012-2013-2014) - Novartis Pharma Serv. AG : Echocardiography in terms of clinical trial; Speaker fee; Advisory Board fee (2014) - Diamedica SIA : Heart failure. Honoraria (2014) - Berlin Chemie Menarini : Heart failure. Speaker fee (2014)
Katus Hugo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca; Bayer; Daiichi Sankyo; Roche Diagnostics, Menarini, : Ticagrelor, Rivaroxaban, Prasugrel, Troponin T, Ranolazine (2012-2013-2014) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca, Bayer Ag, Daiichi Sankyo, MSD, Novartis, Sanofi-Aventis, Servier, Roche Diagnostics : Rivaroxaban, Ticagrelor, Prasugrel, Ranexa, Rasilez (2012-2013-2014) C - Receipt of royalties for intellectual property. - Roche Pharma : Troponin T (2012-2013-2014) D - Research funding (departmental or institutional). - Abbott, Medtronic, St. Jude, Biotronik : Investigator Initiated Trials, Clinical registries (2012-2013-2014)

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kavoliuniene Ausra	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : beta blockers use in CVD (2012-2013) - Servier : RCTs, Speaker's Fee (2013) - Krka Pharma : ARBs - Speaker's fee (2013-2014) - Berlin Chemie AG : BB - Speaker's fee (2013-2014) - Cardioentis : Ularitide vs placebo randomised clinical trial TRUE-AHF (2014)
Keren Andre	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - CardioLogic Innovations : Heart failure diagnosis (2014) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - CardioLogic CO. : Bioimpedance for lung congestion (2012-2013)
Kerimkulova Alina	None declared (2012-2013-2014)
Kirchhof Paulus	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : cardiovascular (2012-2013-2014) - Daiichi Sankyo : cardiovascular (2012-2013-2014) - Medtronic : cardiovascular (2012-2013-2014) - Pfizer : cardiovascular (2012-2013-2014) - St Jude Medical : cardiovascular (2012-2013-2014) - Sanofi Aventis : cardiovascular (2012-2013-2014) - Meda pharma : cardiovascular (2012-2013-2014) - Bristol Myers Squibb : cardiovascular (2012-2013-2014) - Merck Sharp & Dohme : cardiovascular (2012-2013-2014) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2012-2013-2014) - Johnson & Johnson : cardiovascular (2014) - Bayer Healthcare : cardiovascular (2014)

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Portola Pharmaceuticals : cardiovascular (2012)</li> <li>- Boehringer-Ingelheim : cardiovascular (2012-2013-2014)</li> <li>- Bayer Healthcare : cardiovascular (2012-2013-2014)</li> <li>- BMS / Pfizer alliance : cardiovascular (2012-2013-2014)</li> <li>- Gilead : cardiovascular (2013)</li> <li>- Daiichi Sankyo : cardiovascular (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : cardiovascular (2012-2013)</li> <li>- Sanofi Aventis : cardiovascular (2012-2013)</li> <li>- Meda pharma : cardiovascular (2012-2013-2014)</li> <li>- British Heart Foundation : cardiovascular (2014)</li> <li>- European Union (FP7) : cardiovascular (2014)</li> <li>- Daiichi Sankyo : cardiovascular (IIT grant to AFNET) (2014)</li> <li>- St Jude Medical : cardiovascular (IIT grant to AFNET) (2014)</li> <li>- Sanofi Aventis : cardiovascular (IIT grant to AFNET) (2014)</li> <li>- BMS/Pfizer : cardiovascular (IIT grant to AFNET) (2014)</li> <li>- Fondation Leducq : cardiovascular (starting in October 2014) (2014)</li> <li>- German Ministry of Education and Research (BMBF) : cardiovascular (to AFNET) (2014)</li> </ul>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Regado Biosciences : Antithrombotic agents (2012)</li> <li>- Astra Zeneca : Antiplatelet agents (2012-2013-2014)</li> <li>- B.Braun : Surgical instruments (2013-2014)</li> </ul>

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kolh Philippe H	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp &amp; Dohme : Antistaphylococcic vaccine (2012)</p> <p>D - Research funding (departmental or institutional). - St Jude Medical : Cardiac valves (2012-2013) - Boston Scientific : Coronary stents (2012-2013) - Siemens Healthcare : Medical imaging (2012-2013) - Johnson &amp; Johnson : Thoracoscopic devices (2012-2013) - Edwards Lifesciences : Cardiac valves (2012-2013-2014) - Medtronic : Cardiac valves (2012-2013-2014)</p>
Komissarova Svetlana	None declared (2012-2013-2014)
Leenhardt Antoine	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : anticoagulants (2012-2013-2014)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : anticoagulants (2012-2013-2014)</p> <p>D - Research funding (departmental or institutional). - Bristol Myers Squibb : anticoagulants (2012-2013-2014)</p> <p>E - Research funding (personal). - Servier : antiarrhythmic (2012-2013) - Sanofi Aventis : antiarrhythmic (2012-2013-2014) - Meda pharma : antiarrhythmics (2012-2013-2014) - Medtronic : device (2012-2013-2014) - St Jude Medical : device (2012-2013-2014) - Boston Scientific : devices (2012-2013-2014) - Pierre Fabre : Antiarrhythmic (2014)</p>
Lenarczyk Radoslaw	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : Producer of pacemakers, ICDs, CRT-devices (2012-2013-2014)</p>

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lenarczyk Radoslaw	<ul style="list-style-type: none"> <li>- St Jude Medical : Producer of pacemakers, ICDs, CRT-devices (2012-2013-2014)</li> <li>- Biotronik : Producer of pacemakers, ICDs, CRT-devices (2012-2013-2014)</li> <li>- Boehringer-Ingelheim : Producer of drugs (2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Producer of pacemakers, ICDs, CRT-devices (2014)</li> </ul>
Linhart Ales	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension (2012-2013-2014)</li> <li>- Boehringer-Ingelheim : Arterial hypertension, atrial fibrillation (2012-2013-2014)</li> <li>- GlaxoSmithKline : Atherosclerosis (2012-2013-2014)</li> <li>- Merck Sharp &amp; Dohme : Dyslipidemia (2012-2013-2014)</li> <li>- Bayer Schering Pharma : Dyslipidemia, pulmonary hypertension, atrial fibrillation (2012-2013-2014)</li> <li>- Shire HGT : Fabry disease (2012-2013-2014)</li> <li>- Genzyme : Fabry disease (2012-2013-2014)</li> <li>- Actelion : Pulmonary hypertension (2012-2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Shire HGT : Fabry disease (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Shire HGT : Fabry disease (2014)</li> </ul>
Lionis Christos	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Speaker fees (2012-2013)</li> <li>- GlaxoSmithKline : Speaker fees (2013)</li> <li>- Pfizer Hellas : Speaker fees (2013)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- GlaxoSmithKline : speaker fees (2014)</li> <li>- MSD : speaker fees (2014)</li> <li>- Vianex : speaker fees (2014)</li> </ul>



## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lionis Christos	<ul style="list-style-type: none"> <li>- APR : speaker fees (2014)</li> <li>- Pfizer International Operations : speaker fees (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Pfizer : Community acquired pneumonia epidemiological research study. No product or therapeutic area. (2012-2013)</li> </ul>
Lovic Dragan	None declared (2012-2013-2014)
Mairesse Georges H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : NOAC (2012-2013-2014)</li> <li>- Bristol Myers Squibb : NOAC (2012-2013-2014)</li> <li>- Daiichi Sankyo : NOAC (2013-2014)</li> <li>- Bayer Healthcare : NOAC (2013-2014)</li> <li>- Medtronic : pacemakers (2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Dronédarone (2012-2013)</li> <li>- Daiichi Sankyo : NOAC (2012-2013-2014)</li> <li>- Bristol Myers Squibb : NOAC (2012-2013-2014)</li> <li>- Medtronic : Pacemaker (2012-2013-2014)</li> <li>- Sorin Group : Pacemaker (2012-2013-2014)</li> <li>- St Jude Medical : Pacemaker (2012-2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : Pacemaker (2012-2013-2014)</li> </ul>
Michels Michelle	None declared (2012-2013-2014)
Muneretto Claudio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Estech : Atrial Fibrillation (2012-2013-2014)</li> <li>- Atricure : Atrial fibrillation (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sorin Group : Heart valve, extracorporeal circulation (2013-2014)</li> </ul>

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Nesukay Elena	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : cardiology (2012-2013-2014)
Noble Stephane	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : CoreValve (2012-2013-2014) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Cordis : radial intervention (2012-2013-2014)
Ozdemir Huseyin Murat	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : antiplatelet therapy (2012) - Boehringer-Ingelheim : oral anticoagulants (2012-2013-2014) - Pfizer : oral anticoagulants (2012-2013-2014) - Bayer Healthcare : oral anticoagulants (2012-2013-2014) - Bristol Myers Squibb : oral anticoagulants (2012-2013-2014) - Boston Scientific : cardiac pacemakers (2013-2014)
Ponikowski Piotr	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : heart failure (2012) - Cothra : heart failure (2012) - Coridea : heart failure (2012) - Boehringer-Ingelheim : anticoagulant (2012-2013-2014) - Bristol Myers Squibb : anticoagulant (2012-2013-2014) - Respicardia : anticoagulant (2012-2013-2014) - Abbott Vascular : devices (2012-2013-2014) - Novartis : heart failure (2012-2013-2014) - Johnson & Johnson : heart failure (2012-2013-2014) - Bayer Healthcare : heart failure (2012-2013-2014) - Vifor Pharma ltd : heart failure (2012-2013-2014)

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- Pfizer : heart failure, anticoagulant (2012-2013-2014)</li> <li>- Servier : heart failure, coronary artery disease (2012-2013-2014)</li> <li>- Bayer : anticoagulant (2013-2014)</li> <li>- ROSCHE : diabetes (2013-2014)</li> <li>- Cardiorentis : heart failure (2013-2014)</li> <li>- CIBIEM : heart failure (2013-2014)</li> <li>- Amgen : heart failure, lipids (2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Vifor Pharma ltd : heart failure (2012-2013-2014)</li> </ul>
Priori Silvia Giuliana	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : CRM (2012)</li> <li>- Biotronik : CRM (2012)</li> <li>- Transgenomic : Genetics (2012)</li> <li>- Medtronic : CRM (2012-2013)</li> <li>- Medtronic : Cardiac Rhythm Management (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : CRM (2013)</li> <li>- Boston Scientific : Cardiac Rhythm Management (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Gilead : antiarrhythmic drugs (2014)</li> <li>- Boston Scientific : epidemiology of Brugada Syndrome (2014)</li> </ul>
Salvador Taboada Maria Jesus	None declared (2012-2013-2014)
Sekhri Neha	None declared (2012-2013-2014)
Sepp Robert	None declared (2012-2013-2014)

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Skouri Hadi	None declared (2012) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - thoratec;novartis; : Honoraria;Speaker fees (2013-2014)
Smajic Elnur	None declared (2012-2013) E - Research funding (personal). - Sanofi Aventis : Odyssey outcomes, new hypolipemic product, not yet started, one of the researcher in Bosnia and Herzegovina, (2014)
Srbinovska-Kostovska Elizabeta	None declared (2012-2013-2014)
Velchev Vasil	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Inetrventional cardiology (2012-2013-2014) - Astra Zeneca : Ticagrelor, Crestor (2012-2013-2014) - Servier : Trimetazidine, Ivabradine (2012-2013-2014)
Wolpert Christian	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biotronik : ICD Pacemaker (2012-2013) - Medtronic : ICD Ablation pacemaker (2012-2013-2014) - St Jude Medical : ICD Ablation, Pacemaker (2012-2013-2014) - Sorin Group : ICD Pacemaker (2012-2013-2014) - Biotronik : ICD, Ablation, Pacemaker (2014)
Zamorano Gomez Jose Luis	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott Vascular : Help in Design Echocardiographic protocol (2012) - Merck Sharp & Dohme : Lecture (2012) - Daiichii : Atrial Fib (2013) - Merck Sharp & Dohme : Lipid Lowering (2013) - Philips : 3D echo (2014) - MSD : CV risk factors (2014)

## Guidelines on Hypertrophic Cardiomyopathy 2014 (TF20) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<ul style="list-style-type: none"> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- European Research Foundation FP7 : CV Imaging (2012)</li> <li>- European Research FP7 : CV Imaging (2013)</li> <li>- Servier : Imaging in ISchemic patients (2013)</li> <li>- Siemens Healthcare : 3d echo software and free style echo (2014)</li> </ul> </li> <li>C - Receipt of royalties for intellectual property.               <ul style="list-style-type: none"> <li>- Springer : ESC Textbook of CV Imaging (2012-2013)</li> </ul> </li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Astra Zeneca : Clinical trial (2014)</li> <li>- Icaria : Clinical trial (2014)</li> </ul> </li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Achenbach Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : CT (2012-2013)</li> <li>- Servier : Imaging (2012-2013)</li> <li>- Guerbet : Imaging (2012-2013)</li> <li>- Bayer : Anticoagulation (2013)</li> <li>- Behring : Anticoagulation (2013)</li> <li>- Astra Zeneca : Antiplatelet Therapy (2013)</li> <li>- Abbott : Coronary Intervention (2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Coronary Intervention (2013-2014)</li> <li>- Siemens Healthcare : Imaging (2013-2014)</li> </ul>
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2012)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2012-2013-2014)</li> <li>- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014)</li> <li>- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014)</li> <li>- Abbott : transcather mitral valve repair (Mitraclip) (2013-2014)</li> <li>- Direct Flow Medical : transcatheter valve implantation (2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2012-2013-2014)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2012-2013-2014)</li> <li>- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014)</li> <li>- Abbott : transcather mitral valve repair (Mitraclip) (2013-2014)</li> <li>- Direct Flow Medical : transcatheter valve implantation (2013-2014)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bax Jeroen	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Farma (2012-2013-2014)</li> <li>- Edwards Lifesciences : Heart Valves (2012-2013-2014)</li> <li>- GE Healthcare : Imaging (2012-2013-2014)</li> <li>- Lantheus Inc : Imaging (2012-2013-2014)</li> <li>- Boston Scientific : Pacing (2012-2013-2014)</li> <li>- Medtronic : Pacing (2012-2013-2014)</li> <li>- St Jude Medical : Pacing (2012-2013-2014)</li> <li>- Biotronik : Pacing (2012-2013-2014)</li> </ul>
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure and elinogrel (2012)</li> <li>- Bayer Healthcare : Aspirin, rivaroxaban (2012-2013-2014)</li> <li>- Roche Pharma : Dalcetrapib (2012-2013-2014)</li> <li>- Daiichi Sankyo : Prasugrel (2012-2013-2014)</li> <li>- Eli Lilly : Prasugrel (2012-2013-2014)</li> <li>- Astra Zeneca : Ticagrelor (2012-2013-2014)</li> <li>- BMS/Pfizer : Apixaban (2013)</li> <li>- Novartis : Relaxin (2013)</li> <li>- Sanofi Aventis : Clopidogrel (2013-2014)</li> <li>- Pfizer : Apixaban (2014)</li> <li>- Bristol Myers Squibb : Apixaban (2014)</li> <li>- Menarini : Ranolazine (2014)</li> <li>- Novartis : Serelaxin (2014)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	E - Research funding (personal). - Astra Zeneca : Ticagrelor (2012-2013-2014)
Deaton M Christi	None declared (2013-2014)  D - Research funding (departmental or institutional). - Novo-Nordisk : patients with heart failure and diabetes (2012)
Erol Cetin	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Hypertension (2013-2014)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Perindopril (2012) - Menarini : Trandolapril (2012) - Menarini : Hypertension (2013-2014)  C - Receipt of royalties for intellectual property. - Astra Zeneca : Ticagrelor (2012)
Fagard Robert	None declared (2012-2013-2014)
Ferrari Roberto	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulant and diabetes. Dagabitran (2012) - Medical Trials Analysis : Consultant in Clinical Trials (2012) - Servier : Myocardial ischemia and heart failure. Perindopril, ivabradine, amlodipine, trimetazidine (2012) - Novartis : Acute heart failure. Saralaxine (2013-2014) - Boehringer-Ingelheim : Anticoagulants and diabetes. Dagabitran (2013-2014) - Medical Trials Analysis : Consultant in clinical trials - expertise (2013-2014) - Merk Serono : Coronary artery disease, heart failure, beta blockers (2013-2014) - Servier : Myocardial ischemia and heart failure. Perindopril, Ivabradine, Amlodipine, Trimetazidine (2013-2014)  D - Research funding (departmental or institutional). - Fondazione Salvatore Maugeri : General (2012) - Schering-Plough : Anti-platelet agent TRACER (2012-2013-2014)



## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ferrari Roberto	<ul style="list-style-type: none"> <li>- Servier : Perindopril, ivabradine, amlodipine CLARifY and SIGNifY (2012-2013-2014)</li> </ul>
Hasdai David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Pradaxa (2012-2013-2014)</li> <li>- Bayer : Rivaroxiban (2012-2013-2014)</li> <li>- Astra Zeneca : Ticagrelor (2012-2013-2014)</li> </ul>
Hoes Arno	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)</li> <li>- Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014)</li> <li>- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012-2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014)</li> </ul>
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : cardiovascular (2012-2013-2014)</li> <li>- Daiichi Sankyo : cardiovascular (2012-2013-2014)</li> <li>- Medtronic : cardiovascular (2012-2013-2014)</li> <li>- Pfizer : cardiovascular (2012-2013-2014)</li> <li>- St Jude Medical : cardiovascular (2012-2013-2014)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- Sanofi Aventis : cardiovascular (2012-2013-2014)</li> <li>- Meda pharma : cardiovascular (2012-2013-2014)</li> <li>- Bristol Myers Squibb : cardiovascular (2012-2013-2014)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular (2012-2013-2014)</li> <li>- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2012-2013-2014)</li> <li>- Johnson &amp; Johnson : cardiovascular (2014)</li> <li>- Bayer Healthcare : cardiovascular (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Portola Pharmaceuticals : cardiovascular (2012)</li> <li>- Boehringer-Ingelheim : cardiovascular (2012-2013-2014)</li> <li>- Bayer Healthcare : cardiovascular (2012-2013-2014)</li> <li>- BMS / Pfizer alliance : cardiovascular (2012-2013-2014)</li> <li>- Gilead : cardiovascular (2013)</li> <li>- Daiichi Sankyo : cardiovascular (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : cardiovascular (2012-2013)</li> <li>- Sanofi Aventis : cardiovascular (2012-2013)</li> <li>- Meda pharma : cardiovascular (2012-2013-2014)</li> <li>- British Heart Foundation : cardiovascular (2014)</li> <li>- European Union (FP7) : cardiovascular (2014)</li> <li>- Daiichi Sankyo : cardiovascular (IIT grant to AFNET) (2014)</li> <li>- St Jude Medical : cardiovascular (IIT grant to AFNET) (2014)</li> <li>- Sanofi Aventis : cardiovascular (IIT grant to AFNET) (2014)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- BMS/Pfizer : cardiovascular (IIT grant to AFNET) (2014)</li> <li>- Fondation Leducq : cardiovascular (starting in October 2014) (2014)</li> <li>- German Ministry of Education and Research (BMBF) : cardiovascular (to AFNET) (2014)</li> </ul>
Knuuti Juhani	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Lantheus Inc : Perfusion imaging tracer development (2012-2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Vascular inflammation (2012-2013-2014)</li> <li>- Athera : vascular inflammation (2012-2013-2014)</li> <li>- Orion Pharma : Heart failure drug research (2014)</li> </ul>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Regado Biosciences : Antithrombotic agents (2012)</li> <li>- Astra Zeneca : Antiplatelet agents (2012-2013-2014)</li> <li>- B.Braun : Surgical instruments (2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Antistaphylococcic vaccine (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : Cardiac valves (2012-2013)</li> <li>- Boston Scientific : Coronary stents (2012-2013)</li> <li>- Siemens Healthcare : Medical imaging (2012-2013)</li> <li>- Johnson &amp; Johnson : Thoracoscopic devices (2012-2013)</li> <li>- Edwards Lifesciences : Cardiac valves (2012-2013-2014)</li> <li>- Medtronic : Cardiac valves (2012-2013-2014)</li> </ul>
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Heart Failure (2012)</li> <li>- Servier : Heart Failure (2013)</li> <li>- Abbott : MitraClip (2013)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<ul style="list-style-type: none"> <li>- Menarini : nebivolol (2014)</li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Astra Zeneca : Brilique (2012)</li> <li>- Servier : Coversyl (2012)</li> <li>- Abbott Vascular : MitraClip (2012)</li> <li>- Astrazeneca : Dyslipidemia (2013)</li> <li>- Boston Scientific : CRT (2014)</li> <li>- Servier : procoralan (2014)</li> </ul> </li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension (2013)</li> </ul> </li> </ul>
Linhart Ales	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension (2012-2013-2014)</li> <li>- Boehringer-Ingelheim : Arterial hypertension, atrial fibrillation (2012-2013-2014)</li> <li>- GlaxoSmithKline : Atherosclerosis (2012-2013-2014)</li> <li>- Merck Sharp &amp; Dohme : Dyslipidemia (2012-2013-2014)</li> <li>- Bayer Schering Pharma : Dyslipidemia, pulmonary hypertension, atrial fibrillation (2012-2013-2014)</li> <li>- Shire HGT : Fabry disease (2012-2013-2014)</li> <li>- Genzyme : Fabry disease (2012-2013-2014)</li> <li>- Actelion : Pulmonary hypertension (2012-2013-2014)</li> </ul> </li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Shire HGT : Fabry disease (2012)</li> </ul> </li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Shire HGT : Fabry disease (2014)</li> </ul> </li> </ul>
Nihoyannopoulos Petros	<ul style="list-style-type: none"> <li>None declared (2012)</li> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- GSK : Consultant for Imaging studies (2013-2014)</li> </ul> </li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Piepoli Massimo Francesco	<p>None declared (2013-2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Chiesi Pharma : Anti-dyslipidemic therapy (2012)</p>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : heart failure (2012)</li> <li>- Cothera : heart failure (2012)</li> <li>- Coridea : heart failure (2012)</li> <li>- Boehringer-Ingelheim : anticoagulant (2012-2013-2014)</li> <li>- Bristol Myers Squibb : anticoagulant (2012-2013-2014)</li> <li>- Respicardia : anticoagulant (2012-2013-2014)</li> <li>- Abbott Vascular : devices (2012-2013-2014)</li> <li>- Novartis : heart failure (2012-2013-2014)</li> <li>- Johnson &amp; Johnson : heart failure (2012-2013-2014)</li> <li>- Bayer Healthcare : heart failure (2012-2013-2014)</li> <li>- Vifor Pharma ltd : heart failure (2012-2013-2014)</li> <li>- Pfizer : heart failure, anticoagulant (2012-2013-2014)</li> <li>- Servier : heart failure, coronary artery disease (2012-2013-2014)</li> <li>- Bayer : anticoagulant (2013-2014)</li> <li>- ROSCHE : diabetes (2013-2014)</li> <li>- Cardioentis : heart failure (2013-2014)</li> <li>- CIBIEM : heart failure (2013-2014)</li> <li>- Amgen : heart failure, lipids (2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional). - Vifor Pharma ltd : heart failure (2012-2013-2014)</p>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Sirnes Per Anton	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Quintiles on behalf of Novartis : Investig fee CANTOS study (2012)</li> <li>- Merck Sharp &amp; Dohme : Investigator fee HPS2-THRIVE STUDY (2012)</li> <li>- Boehringer-Ingelheim : Investigator Fee Reliable study (2012)</li> <li>- Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012)</li> <li>- GlaxoSmithKline : Investig fee HZC113108 and LPL100601 studies (2012-2013)</li> <li>- SticaresInterACt on behalf of Servier : Investig Fee SIGNIFY study (2012-2013)</li> <li>- NORMA on behalf of Janssen Cilar : Invest fee CANVAS study (2012-2013-2014)</li> <li>- Amgen : Speeker fee (2013)</li> <li>- Pfizer : speeker fee (2013)</li> <li>- Quintiles on behalf Garfield AF Registry : Fee Garfield AF registry (2013-2014)</li> <li>- Novartis : Investigatoprs fee CANTOS study (2013-2014)</li> </ul>
Tamargo Juan Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- sanodi-aventis : Dronedarone-antiarrhythmic agent (2012)</li> <li>- Menarini : Ranolazina (2013)</li> <li>- Menarini : Ranolazine (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca (Unrestricted Grant) : Candesartan, Felodipine, Atenolol (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Unrestricted Grant (2013)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Astra -Zeneca Foundation (NON-PROFIT FOUNDATION). two years Unrestricted Grant : None (2012)</li> <li>- Instituto de Salud Carlos III. Ministerio de Economía y Competitividad. Gobierno de España : No product/device (2014)</li> </ul>
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Aspirin, Rivaroxaban (2012)</li> <li>- Amgen : Darbopietin (2012)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Tendera Michal	<ul style="list-style-type: none"> <li>- Servier : Ivabradine, Phase II investigational products (2012)</li> <li>- Amgen : Darbopoietine (2013)</li> <li>- Bayer : Aspirin, Acarbose (2013-2014)</li> <li>- Servier : Ivabradine (2013-2014)</li> <li>- Janssen Cilag : Rivaroxaban (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Ivabradine, Phase II investigational products (2012)</li> <li>- Servier : Ivabradine (2014)</li> <li>- Janssen-Cilag : Rivaroxaban (2014)</li> </ul>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Cardiomems : implanted pulmonary artery pressure sensor (2012)</li> <li>- United Therapeutics : Pulmonary arterial hypertension (2012)</li> <li>- Lilly : pulmonary arterial hypertension - tadalafil (2012)</li> <li>- AOP Orphan Pharmaceuticals : Pulmonary arterial hypertension - treprostinil (2012)</li> <li>- Bristol Myers Squibb : thromboembolic disease - Apixaban (2012)</li> <li>- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2012-2013)</li> <li>- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2012-2013-2014)</li> <li>- Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2012-2013-2014)</li> <li>- Bristol Myers Squibb : Pulmonary arterial hypertension (2013)</li> <li>- Lilly : pulmonary arterial hypertension - ambrisentan (2013)</li> <li>- Novartis : pulmonary hypertension (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Thromboembolic disease (2012)</li> <li>- Bayer Healthcare : Pulmonary hypertension (2012-2013-2014)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Wijns William	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Tryton : device (2012)</li> <li>- Astra Zeneca : pharma (2012)</li> <li>- Biosensors : device (2012-2013-2014)</li> <li>- Boston Scientific : device (2012-2013-2014)</li> <li>- Edwards Lifesciences : device (2012-2013-2014)</li> <li>- Medtronic : device (2012-2013-2014)</li> <li>- St Jude Medical : device (2012-2013-2014)</li> <li>- Biotronik : device (2012-2013-2014)</li> <li>- Terumo Inc : device (2012-2013-2014)</li> <li>- Abbott Vascular : device (2012-2013-2014)</li> <li>- Cordis : device (2012-2013-2014)</li> <li>- Orbus Nech : device (2012-2013-2014)</li> <li>- MICELL : device (2012-2013-2014)</li> <li>- Vessix : device (2012-2013-2014)</li> <li>- GlaxoSmithKline : drug (2012-2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Cardio3 Biosciences : cell therapy (2012-2013-2014)</li> <li>- Boston Scientific : device (2012-2013-2014)</li> <li>- Medtronic : device (2012-2013-2014)</li> <li>- St Jude Medical : device (2012-2013-2014)</li> <li>- Biotronik : device (2012-2013-2014)</li> <li>- Abbott Laboratories : device (2012-2013-2014)</li> </ul>



## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Wijns William	<ul style="list-style-type: none"> <li>- MICELL : device (2012-2013-2014)</li> <li>- Therabel : drug (2012-2013-2014)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biosensors : Stent (2012)</li> <li>- Boston Scientific : Stent (2012)</li> <li>- Cordis : Stent (2012)</li> <li>- Edwards Lifesciences : TAVI (2012)</li> <li>- Astra Zeneca : Antiplatelet drug (2012-2013)</li> <li>- Eli Lilly : Antiplatelet drug (2012-2013)</li> <li>- Abbott : Stent (2012-2013)</li> <li>- Medtronic : Stent (2012-2013)</li> <li>- Biotronik : Stent (2012-2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Stent (2012)</li> <li>- Biosensors : Stent (2012)</li> <li>- Medtronic : Stent (2012)</li> <li>- Cordis : Stent (2012)</li> <li>- St Jude Medical : OCT (2012-2013-2014)</li> <li>- Biotronik : Stent (2012-2013-2014)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : Help in Design Echocardiographic protocol (2012)</li> <li>- Merck Sharp &amp; Dohme : Lecture (2012)</li> <li>- Daiichii : Atrial Fib (2013)</li> <li>- Merck Sharp &amp; Dohme : Lipid Lowering (2013)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<ul style="list-style-type: none"> <li>- Philips : 3D echo (2014)</li> <li>- MSD : CV risk factors (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- European Research Foundation FP7 : CV Imaging (2012)</li> <li>- European Research FP7 : CV Imaging (2013)</li> <li>- Servier : Imaging in ISchemic patients (2013)</li> <li>- Siemens Healthcare : 3d echo software and free style echo (2014)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Springer : ESC Textbook of CV Imaging (2012-2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Clinical trial (2014)</li> <li>- Ikaria : Clinical trial (2014)</li> </ul>